Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 16/20 | 0.62 |
| ▸ | THRA | P10827 | 15/20 | 0.62 |
| ▸ | RORC | P51449 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514228 | 0.88 | THRB (0.60) | THRBTHRARORCHTR2AHTR2C | |
| SCHEMBL6512438 | 0.86 | THRA (0.73) | THRBTHRA | |
| SCHEMBL6521769 | 0.85 | THRB (0.57) | THRBTHRARORCHTR2AHTR2C | |
| SCHEMBL6512167 | 0.85 | THRB (0.74) | THRBTHRARORC | |
| SCHEMBL6512367 | 0.84 | THRB (0.63) | THRBTHRARORCHTR2AHTR2C | |
| SCHEMBL6524689 | 0.83 | THRB (0.77) | THRBTHRARORCHTR2AHTR2C | |
| SCHEMBL6514002 | 0.81 | THRA (0.63) | THRBTHRAMTNR1AMTNR1B | |
| SCHEMBL6524751 | 0.81 | THRB (0.62) | THRBTHRARORCHTR2AHTR2C | |
| SCHEMBL6518525 | 0.81 | THRA (0.68) | THRBTHRA | |
| SCHEMBL6515424 | 0.80 | THRA (0.67) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | THRB 1772/4885THRA 2460/4885RORC 468/4885 |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | HMGCR, CYP46A1, EBP | THRB 1835/4885THRA 1917/4885RORC 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.